RP2
Metastatic Uveal Melanoma
Key Facts
About Replimune
Replimune is a clinical-stage biotech with a mission to revolutionize cancer treatment through comprehensive activation of tumor-specific immune responses. The company's core achievement is the development of its proprietary RPx platform, a next-generation, engineered HSV-1-based oncolytic immunotherapy, which is now in late-stage clinical trials. Its strategy focuses on advancing a pipeline of wholly-owned assets across solid tumors, with a lead program (RP1) in advanced melanoma under regulatory review (PDUFA July 22, 2025), supported by in-house manufacturing and key commercial partnerships.
View full company profileAbout Replimune
Replimune is a clinical-stage biotech with a mission to revolutionize cancer treatment through comprehensive activation of tumor-specific immune responses. The company's core achievement is the development of its proprietary RPx platform, a next-generation, engineered HSV-1-based oncolytic immunotherapy, which is now in late-stage clinical trials. Its strategy focuses on advancing a pipeline of wholly-owned assets across solid tumors, with a lead program (RP1) in advanced melanoma under regulatory review (PDUFA July 22, 2025), supported by in-house manufacturing and key commercial partnerships.
View full company profileTherapeutic Areas
Other Metastatic Uveal Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Zepzelca (lurbinectedin) | PharmaMar | Phase 2 |
| FHD-286 | Foghorn Therapeutics | Phase 1 |